Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 142 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Sorafenib Hypophosphatemia Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				12345 N.A., NCT00622479


2.		A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				11718 NCT00111007

Last Modified: 9/19/2008 First Published: 5/11/2006


3.		Phase III Randomized Study of Adjuvant Sunitinib Malate Versus Sorafenib in Patients With Resected Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				ECOG-E2805 E2805, CALGB-E2805, SWOG-E2805, CAN-NCIC-E2805, NCT00326898


4.		A Phase III Randomized, Double-Blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				12006 EudraCT 2006-002688-26, NCT00449033

Last Modified: 9/28/2007 First Published: 6/21/2007


5.		Phase III Randomized Study of Sorafenib Tosylate in Patients With Resected Primary Renal Cell Carcinoma at High- or Intermediate-Risk of Relapse

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Over 18				Other				MRC-RE05-SORCE MRC-RE05-SORCE, EUDRACT ID 2006-006079-19, EU-20734, NCT00492258, SORCE, ISRCTN38934710


6.		Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				12750 NCT00478114

First Published: 10/2/2007


7.		Phase III Randomized Study of Gemcitabine Hydrochloride and Sorafenib Tosylate in Patients With Locally Advanced or Metastatic Adenocarcinoma of the Pancreas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				IPC-BAYPAN BAYPAN, INCA-RECF0426, IPC-2005-006, NCT00541021


8.		Sorafenib Long Term Extension Program (STEP)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				16 and over				Pharmaceutical / Industry				12311 EudraCT 2007-002604-17, NCT00625378


9.		Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular CarcinoMa (STORM)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				12414 2008-001087-36, STORM, NCT00692770


10.		Phase 3 Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				A6181170 NCT00699374

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute